Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20030065002 A1
Publication typeApplication
Application numberUS 10/143,111
Publication dateApr 3, 2003
Filing dateMay 10, 2002
Priority dateMay 11, 2001
Also published asCA2446550A1, CA2446550C, CN1525851A, DE60238756D1, EP1387673A1, EP1387673B1, US8969369, US9056051, US9084729, US9161937, US9168252, US9283216, US9283221, US9345701, US9358230, US20080069881, US20120252832, US20130172382, US20140107146, US20140135355, US20140194456, US20150258087, US20150258088, US20160008346, US20160008351, US20160151353, US20160151354, WO2002092060A1
Publication number10143111, 143111, US 2003/0065002 A1, US 2003/065002 A1, US 20030065002 A1, US 20030065002A1, US 2003065002 A1, US 2003065002A1, US-A1-20030065002, US-A1-2003065002, US2003/0065002A1, US2003/065002A1, US20030065002 A1, US20030065002A1, US2003065002 A1, US2003065002A1
InventorsFrank Caruso, Huai-Hung Kao
Original AssigneeEndo Pharmaceuticals, Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Abuse-resistant controlled-release opioid dosage form
US 20030065002 A1
Abstract
Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.
Images(8)
Previous page
Next page
Claims(20)
What is claimed is:
1. An oral pharmaceutical composition comprising:
a controlled release matrix;
an opioid agonist;
an opioid antagonist having greater antagonistic effect when administered parenterally than when administered orally;
wherein said opioid antagonist is present in the composition in an orally effective amount for blocking the opioid effect and/or inducing withdrawal when the controlled release matrix is defeated and the composition improperly administered for immediate release;
wherein said controlled release matrix is selected and incorporated for controlling the release rate of the opioid antagonist such that antagonist levels are not effective for blocking the opioid effect by blocking both the inhibitory and excitatory receptors or for attenuating opioid side effects by selectively blocking the excitatory receptors under proper oral administration regimes.
2. The pharmaceutical composition according to claim 1 wherein the release rate of the opioid antagonist is approximately 100 to approximately 25 percent of the release rate of the opioid agonist.
3. The pharmaceutical composition according to claim 1 wherein the release rate of the opioid antagonist is approximately 100 percent of the release rate of the opioid agonist.
4. The pharmaceutical composition according to claim 1 wherein the release rate of the opioid antagonist is approximately 50 percent of the release rate of the opioid agonist.
5. The pharmaceutical composition according to claim 1 wherein the release rate of the opioid antagonist is approximately 25 percent of the release rate of the opioid agonist.
6. The pharmaceutical composition according to claim 1 wherein the oral:parenteral potency ratio of the opioid antagonist is at least about 10:1.
7. The pharmaceutical composition according to claim 1 wherein the oral:parenteral potency ratio of the opioid antagonist is at least about 25:1.
8. The pharmaceutical composition according to claim 1 wherein the oral:parenteral potency ratio of the opioid antagonist is at least about 100:1.
9. The pharmaceutical composition according to claim 1, wherein said opioid agonist is selected from the group consisting of morphine, oxycodone, levorphenol, meperdine, hydrocodone, codeine, dihydrocodeine, hydromorphone, propoxyphene, methadone, and oxymorphone.
10. The pharmaceutical composition according to claim 1 wherein the opioid antagonist is selected from the group consisting of naloxone; naltrexone; N-cyclo propylmethyl-7,8-dihydro-14-hydroxynormorphinone; and 21-cyclopropyl z, -(1-hydroxy-1-methylethyl)-6,14-endo-ethano-tetrahydrooripavine (or diphenorphine) and the pharmaceutically-acceptable salts thereof.
11. The pharmaceutical composition according to claim 1 wherein said opioid antagonist is naloxone.
12. The pharmaceutical composition according to claim 1 wherein said opioid agonist is oxycodone.
13. The pharmaceutical composition according to claim 1 wherein said opioid agonist is present in concentration pharmaceutically equivalent to oxycodone doses of approximately 10-160 mg.
14. The pharmaceutical composition according to claim 1, wherein the release rate of the antagonist is such that a single dose of the composition does not render available an orally effective amount of antagonist, yet when two or more doses of the composition are combined—with or without crushing—to achieve an abusive dose of the opioid agonist, the opioid antagonist is available at orally effective blocking levels.
15. A pharmaceutical composition comprising:
a controlled release matrix;
an opioid agonist;
an opioid antagonist having greater antagonistic effect when administered parenterally than when administered orally;
wherein said opioid antagonist is present in the composition in an amount proportional to the number of abusive doses of the opioid agonist in the composition such that if the CR matrix is defeated and two or more doses of the composition are combined to yield an abusive dose of the opioid agonist, the amount of opioid antagonist will suffice to block the opioid effect and/or induce withdrawal when taken orally;
wherein said controlled release matrix is selected and incorporated for controlling the release rate of the opioid antagonist such that antagonist levels are not effective for blocking the opioid effect by blocking the inhibitory and excitatory receptors or attenuating opioid side effects by selectively blocking the excitatory receptors under proper oral administration regimes.
16. The pharmaceutical composition according to claim 15, wherein the release rate of the antagonist is such that a single dose of the composition does not render available an orally effective amount of antagonist, yet when two or more doses of the composition are combined—with or without crushing—to achieve an abusive dose of the opioid agonist, the opioid antagonist is available at orally effective blocking levels.
17. An oral pharmaceutical composition comprising:
a controlled release matrix;
approximately 10-160 mg oxycodone;
approximately 2-160 mg naloxone;
wherein the ratio of oxycodone to naloxone is approximately 4-5:1 to 1:1;
wherein said controlled release matrix is selected and incorporated for controlling the release rate of the oxycodone for maintaining pharmaceutical effectiveness for a period up to 12 hours and for controlling the release rate of the naloxone such that naloxone levels are not effective for blocking the opioid effect by blocking both the inhibitory and excitatory receptors or for attenuating opioid side effects by selectively blocking the excitatory receptors under proper oral administration regimes.
18. An oral pharmaceutical composition comprising, in % by weight:
about 3-35% opioid agonist;
about 2-20% opioid antagonist;
about 10-50% microcrystalline cellulose, NF;
about 30-70% ammonio methacrylate copolymer, NF; and
at least one excipient selected from the group consisting of:
up to about 5% colloidal silicon dioxide, NF;
up to about 5% sodium lauryl sulfate, NF;
up to about 2% magnesium hydroxide, USP;
up to about 15% povidone, USP;
up to about 5% stearic acid, NF; and
up to about 5% magnesium stearate, NF;
wherein said composition is a controlled release formulation adapted to release the oxycodone at a therapeutically effective rate, and to release said naloxone at a rate ineffective for blocking the opioid effect and/or inducing withdrawal when the controlled release formulation is taken orally in intact form.
19. The oral pharmaceutical composition according to claim 18, wherein said opioid agonist is selected from the group consisting of morphine, oxycodone, levorphenol, meperdine, hydrocodone, codeine, dihydrocodeine, hydromorphone, propoxyphene, methadone, and oxymorphone and the opioid antagonist is selected from the group consisting of naloxone; naltrexone; N-cyclo propylmethyl-7,8-dihydro-14-hydroxynormorphinone; and 21-cyclopropyl z, -(1-hydroxy-1-methylethyl)-6,14-endo-ethano-tetrahydrooripavine (or salts thereof.
20. The oral pharmaceutical composition according to claim 18 wherein said opioid agonist is oxycodone hydrochorlide and said opioid antagonist is naloxone.
Description
  • [0001]
    This application claims benefit of priority to U.S. Provisional Application No. 60/290,439 filed on May 11, 2001.
  • FIELD OF THE INVENTION
  • [0002]
    The present invention relates to controlled-release analgesic pharmaceutical formulations. More specifically, the invention relates to abuse-deterring controlled-release analgesic tablets.
  • BACKGROUND OF THE RELATED ART
  • [0003]
    Opioid compounds have long been known both for their powerful analgesic properties, and for their strong potential for abuse. While highly effective at controlling pain, opioids can also be addictive. Abuse of opioids, particularly heroin, but also including morphine, codeine, oxycodone, hydromorphone, oxymorphone, and others, is a problem in modem society. Opioid addicts can obtain drugs from a variety of illicit sources. These street drugs are of questionable quality. Therefore, to potential abusers, prescription pharmaceutical opioids can be particularly attractive as a drug source because of their high purity and dependable dosage.
  • [0004]
    Abusers extract the pharmaceutical opioid, and other constituents, from the tablets. To do so, the tablets are crushed and often dissolved. The result may be further treated before it is ultimately injected or snorted to achieve a “high”. This type of intravenous or intranasal abuse is well documented.
  • [0005]
    The potential for abuse of pharmaceutical opioids is not a new problem. To combat the effects of opioid abuse, opioid antagonists have been used to block the euphoria associated with opioid abuse, and to induce withdrawal symptoms in addicts. One opioid antagonist used previously, and even now, is naloxone. Naloxone is a powerful antagonist of the opioid receptor. Naloxone is highly effective when taken parenterally, but poorly effective when taken orally because of its metabolism in the liver and, thus, has a high oral:parenteral potency ratio. When injected in humans, amounts as small as 0.2-0.4 mg can block the opioid receptors and prevent the user from experiencing the drug's effects, whether analgesia or mood alteration, euphoria. Because of the high oral:parenteral potency ratio (˜100) the antagonist action of oral doses of naloxone is much lower than the action of injections of naloxone. Because antagonists such as naloxone are less effective when taken orally, they have not been used to deter oral abuse and have been limited to deterring parenteral or intranasal abuse.
  • [0006]
    Recently however, a new form of abuse of opioid agonists has emerged involving oral abuse instead of abuse by injection or snorting. This practice has emerged largely because of the availability of high-opioid content controlled release (CR) formulations. “Chewing” involves crushing the opioid formulation and taking the entire contents, meant for 2 or more doses, at once. This practice releases all the opioid at once to generate a “high.” The crushing may take place in the mouth as suggested by the name, but also may occur by other means to make the opioid readily available including, crushing or dissolving the tablet prior to injection or administered intransally.
  • [0007]
    Recently, high potency prescription opioid tablets containing large milligram doses of opioids have been introduced. These tablets are controlled release tablets and are designed to provide pain relief for 12 hours or more. Because the tablets have action over a long time period (12 hours instead of 4 hours for immediate release tablets), the tablets contain much higher quantities of opioid compounds. For potential abusers, these tablets are very attractive. Their high dosages make them a compact way to access large amounts of opioid. The fact that they are pharmaceuticals guarantees both the quality and quantity of drug in the tablet. Thus, the potential abuser knows he or she is obtaining a high purity drug in a known dosage. Prior oral opioid dosage formulations contained relatively low doses of opioid and were not generally targets for oral abuse. Their immediate release formulations release the opioid all at once, but with low amounts of opioid that would not be sufficient for oral abuse without putting several low dosage units together. In contrast, abusers have found that the new CR tablets contain large doses of opioid, which can be abused orally by chewing the tablets or crushing them to release all of the opioid at one time (immediate release). The present invention deters such oral abuse.
  • [0008]
    Oxycontin®, a controlled release oxycodone tablet from Purdue Pharma, is available in strengths as high as 160 mg oxycodone per tablet. The high opioid content makes these tablets especially attractive to abusers. Illegal trade in controlled release opioid tablets is becoming more prevalent. In order to obtain a euphoric effect (high) from such tablets, an abuser may crush the tablet and extract the opioid compound by dissolution for injection, or intranasal administration. Also, the abuser can achieve a euphoric effect from the drug by simply taking the drug orally, after chewing the tablet or grinding it to break the controlled release matrix and converting it to an immediate release product. Therefore, it would be desirable to have a formulation which would prevent the oral abuse of controlled release tablets if crushed to convert it to an immediate release product, without significantly affecting the analgesic action of opioid compounds in the intact controlled release tablet.
  • [0009]
    WO 01/58447 discloses pharmaceutical combinations of opioid agonists and antagonists in a controlled release matrix. The antagonist is present and released in amounts, over time, that attenuate or reduce the side effects of the opioid agonist, yet in amounts insufficient to block the opioid effect. The preferred antagonist is Naltrexone, which is highly effective when administered orally or parenterally. The antagonist is released only in very small amounts, 100-1000 times less than the opioid. WO '447 is silent with respect to including an anti-abusive amount of antagonist in the dose to prevent abuse. The intravenous use of small amounts of naloxone, 0.25 or 1 μg kg−1hr−1, is also disclosed as having attenuating effects.
  • [0010]
    WO '447 does not present release rates for the antagonist in its CR formulation, but directs those skilled in the art to the Crain patents (U.S. Pat. Nos. 5,767,125; 5,580,876; 5,512,578; and 5,472,943). The Crain patents collectively disclose instant release formulations with “ultra-low” doses of certain antagonists to selectively block only the excitatory opioid receptors to attenuate opioid side effects, without blocking inhibitory receptors, which would lead to opioid blocking. These doses are on the order of pico-molar amounts. Crain '578 suggests that only naltrexone is useful in oral administration and that 1 μg doses are sufficient for attenuating opioid side effects by selectively blocking the excitatory opioid receptors and leaving the inhibitory opioid receptors free for receiving the opioid agonist (which may be administered in lower than normal doses with similar analgesic effect). The normal oral dose of naltrexone is about 50 mg versus “ultra low” does of 1 μg of naltrexone described in Crain '578 patent.
  • [0011]
    The prior art does not discuss controlled release formulation containing agonist and antagonist to deter abuse. Accordingly, there is a need for a composition that deters abuse in the high opioid-content controlled release formulation prevalent today.
  • SUMMARY OF THE INVENTION
  • [0012]
    Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist having a high oral:parenteral potency ratio (i.e. oral:parenteral>1), such as naloxone, at a level insufficient to block the opioid effects or to attenuate the opioid side-effects in the controlled release formulation administered over an extended period, but above that needed to suppress the euphoric effect of the opioid if administered all at once. If the combination tablet is crushed to break the controlled release properties, the opioid and opioid antagonist is released as an immediate release product in a single dose, and the antagonist blocks the euphoric effects of the agonist. The opioid antagonist is contained in a controlled-release matrix and released over time, with the opioid agonist.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0013]
    The present invention employs the principle that certain opioid antagonists are ineffective in low oral doses. Therefore, one can administer a low oral dose over a long period of time (controlled release) from a tablet containing a large, orally effective amount of antagonist, without adversely affecting the action of the opioid. However, if the antagonist is administered all at once, it will block the opioid effect and may induce withdrawal in dependent individuals.
  • [0014]
    The present invention is intended for use in controlled release compositions. The term, “controlled release” or “CR” when used herein, is intended to refer to tablets intended to release an active pharmaceutical ingredient over an extended period of time, usually over 4 hours, generally 8-12 or up to 24 hours. One method of determining this is to check the intended dosing schedule. Any tablet intended to be taken less frequently than once every four hours should be considered controlled release regardless of labeling as controlled release, sustained release, extended release, etc. Often, these tablets contain polymeric matrices which may be cross-linked. Examples of such controlled release formulations are the Contin® system, produced by Purdue Fredrick Pharmaceuticals, or the TimerX® system by Pennwest Pharmaceuticals. Other controlled release polymers can also be used, such as methacrylate (Eudragit®), hydroxylpropyl methylcellulose (HPMC), or Carbopol®. The present invention may be used with these or other controlled release formulations.
  • [0015]
    The tablet of the present invention contains an opioid agonist in a controlled release matrix, along with an opioid antagonist. The antagonist is present at such a level, and dispensed at such a rate, that it will not block the action of the opioid agonist when an intact controlled release tablet is taken orally. Crushing the tablet will release sufficient antagonist all at once as an immediate release formulation to block the opioid response and also, induce abstinence. Antagonists need to reach an effective dose to work, so their slow release coupled with fast metabolism means they are maintained at ineffective, low levels in normal, recommended, therapeutic, non-abusive use. This low level of antagonist can be released over a long time period without affecting the therapeutic action of the opioid agonist. Even with sustained release over such long periods, the antagonist does not accumulate to blocking levels, since it is metabolized before it can accumulate to such levels. Because of the nature of the opioid antagonist action, the level of antagonist should be varied with the opioid dosage of the tablet. Also, depending on the antagonist, the oral:parenteral potency ratio, and the release rates, the levels of antagonists employed will vary. Regardless, there should be sufficient antagonist to block the opioid effect (high) and induce withdrawal in dependent individuals, if the tablet is crushed, converting the formulation to immediate release. Under normal conditions, the release rate is not sufficient for blocking the opioid effect nor suitable for selectively blocking the excitatory opioid receptors to attenuate opioid side effects. For Naloxone, the presently preferred antagonist, it is believed that 15 mg (immediate release) should begin to block the opioid receptors and initiate withdrawal.
  • [0016]
    The specific opioid agonists, antagonists, CR matrices, and the combinations disclosed herein are merely exemplary. Other agonists, antagonists, matrices, and combinations may be used in conjunction with the teachings herein.
  • [0017]
    The opioid agonist can be any agonist in general use as an analgesic, including, but not limited to, morphine, oxycodone, levorphenol, meperdine, hydrocodone, codeine, dihydrocodeine, hydromorphone, propoxyphene, methadone, and oxymorphone. Specifically, any addictive opioid in a controlled release dosage form is the target of the present invention. Most particularly, controlled release oxycodone has recently been the target of abuse, and would therefore make a good candidate for use in the present invention. Of course, the release rate of the opioid agonist is established to achieve the desired analgesic effect.
  • [0018]
    Potency of the antagonist is measured as the oral:parenteral potency ratio, which indicates the amount of antagonist required orally to achieve an equivalent effect to an effective parenteral dose. For example, an antagonist having an oral:parenteral potency ratio of 10:1 requires 10 times the parenteral dose to be effective orally. The opioid antagonists used herein will have greater antagonistic effect when administered parenterally than when administered orally (oral:parenteral potency ratio>1). Accordingly, the desired antagonists block the opioid effect and induce withdrawal when administered at relatively low levels parenterally or intranasally. At the same time, these antagonists require relatively large levels to be effective when administered orally for recommended, therapeutic use. Thus, effective parenteral/intranasal doses are ineffective when administered orally. Preferably, the oral:parenteral potency ratio is at least approximately 10:1, more preferably at least approximately 25:1, and most preferably at least approximately 100:1 as is the case with Naloxone. Appropriate opioid antagonists having substantially greater effectiveness when administered by injection than when administered orally, include, but are not limited to: naloxone; naltrexone; N-cyclo propylmethyl-7,8-dihydro-14-hydroxynormorphinone or 21 cyclopropyl z, -(1-hydroxy-1-methylethyl)-6,14-endo-ethano-tetrahydrooripavine (or diphenorphine); and the pharmaceutically-acceptable salts thereof.
  • [0019]
    It has previously been known that opioid antagonists, such as naloxone, can block opioid receptors and reduce or eliminate the effect of opioids. Such antagonists are useful in treating opioid overdoses and to help treat addiction, in some cases. By blocking opioid receptors, the antagonists reverse and block the response to opioids. The high oral:parenteral potency ratio antagonists, such as naloxone, while very effective when injected, are significantly less effective when taken orally. Therefore, a dosage form designed for oral administration can have a significant amount of opioid antagonist, without adversely affecting the therapeutic efficacy of the opioid. Similarly, these levels of antagonists do not attenuate the side effects of the opioid. Such an antagonist would be effective in deterring intravenous or intranasal abuse when present in low levels, but would be ineffective in deterring oral abuse. Were the tablets to include sufficient antagonist to deter oral abuse, the antagonist would also reduce or inhibit the therapeutic efficacy of the drug. A tablet containing an orally effective amount of antagonists in a CR formulation releasing ineffective amounts of antagonist under normal use would be effective against both oral and parenteral abuse, without minimizing the effectiveness of the opioid under normal use.
  • [0020]
    The amount of antagonist in the composition will depend on the relative strength of the antagonist, the amount and strength of the opioid, the release rate of the antagonist, and the oral:parenteral potency ratio. In any event, the combination of antagonist type, oral:parenteral potency ratio, quantity, and release rate do not result in blockage of the opioid effect or attenuation of its side effects, when administered orally in its intended, intact dosage form.
  • [0021]
    Strengths of controlled release opioid tablets vary with the particular opioid used. In the case of oxycodone, strengths of 10, 20, 40, 80, and 160 mg may be used in a controlled release formula. The amount of opioid antagonist (such as naloxone) in such a tablet may also vary from about 2 mg to 40 mg or more. There should be at least 5 to 20 mg (preferably 10 to 20 mg) of naloxone in a tablet to prevent oral abuse by chewing a number of small, low dose tablets or a higher strength tablet. That is, the accumulation of an abusive dose by combining 2 or more low-dose tablets should also accumulate an effective amount of antagonist. Higher dose opioid tablets should contain an effective amount of antagonist without accumulation. Prevention of abuse by parenteral or intranasal administration will also be accomplished, since in the case of injection or snorting, only about 0.2 to 0.4 mg naloxone is needed to antagonize the opioid effect, to induce abstinence in dependent individuals, and to prevent abuse. Therefore the larger amount needed to prevent oral abuse will necessarily prevent abuse by injection or intranasal administration as well.
  • [0022]
    For oxycodone tablets of 10 or 20 mg tablet strength, the amount of naloxone, opioid antagonist used can range from 5 to 40 mg. As the tablet strength rises, the ratio of opioid to opioid antagonist varies from 1:3 to 4:1, since a 160 mg opioid tablet may contain 80 mg opioid antagonist. Although the ratio can vary, it is preferable to select one ratio for all tablet strengths. Physicians prefer to titrate patients using several low dose tablets which add up to the desired dosage. This is easiest if a constant ratio is maintained. Thus, a constant ratio across tablet strengths is useful even though that ratio can be any appropriate ratio in the range set forth above.
  • [0023]
    Drug abusers are creative when finding ways to defeat anti-abusive measures. Currently, several methods of oral abuse are contemplated. As discussed above, it should be remembered that the compositions of the invention contain sufficient antagonist to be effective orally and, therefore, necessarily contain a parenterally or intranasally effective blocking amount. Accordingly, parenteral and intranasal abuse are not discussed here.
  • [0024]
    Abusers may “chew” a single large dose tablet to achieve instant release of an abusive dose of opioid. Compositions containing these abusive amounts of opioid should contain enough antagonist to block oral abuse by “chewing.”
  • [0025]
    Two or more lower dose tablets may be “chewed” together to achieve an abusive dose. To the extent that each tablet itself does not contain an orally, effective amount of antagonist, when combined to an abusive dose, the combined antagonist should be orally effective. That is if, for example, a 10 mg tablet is not sufficient to achieve a high, it need not contain the full orally effective amount of antagonist. If two 10 mg tablets are sufficient for a high, they then should contain a combined amount of antagonist which is effective orally for blocking the opioid effect.
  • [0026]
    Additionally, two or more high-dose tablets could be taken orally, without crushing, to achieve a “high.” Such a combination would take advantage of the CR properties to sustain a high for the entire dosage period up to 12 hours. This type of abuse is uncommon since most abusers want the instant high or rush afforded by the immediate release of the crushed tablets. Such a combination, according to one embodiment of the invention, should also release a blocking amount of antagonist when taken orally without chewing. This arrangement would also prevent the dire effects of accidental overdose. Although this type of arrangement would be beneficial in many situations, it could limit a prescribing doctor's options, and therefore, may not be appropriate in all situations. Tablets according to this embodiment are not preferred, but are certainly within the scope of the invention.
  • [0027]
    Tablets according to the invention may take into consideration any of the above abusive regimes individually or any combination thereof.
  • [0028]
    The basic underlying premise of the invention is that the tablet contains 1) an amount of antagonist which is orally effective for blocking the opioid effect and 2) that the antagonist is available, normally, only at levels that are ineffective to block the opioid effect or to attenuate the opioid side-effects. One of the ways to achieve this is to control the release rate of the antagonist. The release rate of the antagonist is best thought of in terms of a percent of the release rate of the opioid agonist. The rate is controlled between approximately 100%-0% of the release rate of the opioid, preferably 100%-25%. Table 1 shows release rates of opioid and antagonist as % released. In the case of 0%, the antagonist is never released unless the tablet is crushed. But, that is the subject of another application.
  • [0029]
    In the case of Naloxone, the short half-life (about one hour) ensures that the Naloxone does not accumulate to blocking levels, even when released at the same rate as the opioid. In slower release formulations (50% and 75%), the unreleased portion remaining after 10-12 hours passes to the large intestine where the absorption rate is much slower than in the stomach and small intestine. Accordingly, the amount of antagonist released beyond 10-12 hours does not contribute to any blocking or attenuating effect.
  • [0030]
    These release rates ensure that under normal usage the antagonist has no blocking or attenuating effect. Simultaneously, however, an orally effective blocking dose of the antagonist is present in the event that the CR properties are defeated.
  • [0031]
    The type and application of CR matrix used will determine release rates. Manipulation of release rates, even of two compounds with two different rates is—known in the art. Any known or later developed CR techniques may be used. It is important to remember though, that the antagonist should not be readily distinguishable or separable from the agonist, since would be abusers could possibly use mechanical separation techniques prior to defeating the CR formulation.
    TABLE 1
    Release Rates from CR formulation
    ANTAGONIST
    (as % of AGONIST release rate)
    AGONIST 100% 50% 25%
     1 HR 20-30% 20-30% 10-15% 5-7.5%
     4 HRS 60-70% 60-70% 30-35% 15-17.5%
    10 HRS >90% >90% 45-50% 22.5-25%   
  • [0032]
    Release rates are a percentage of agonist or antagonist with respect to its total content in the composition.
  • [0033]
    The tablets may be made by any traditional method of manufacture of controlled release tablets. Two principal processes are wet process (including wet granulation) and dry process (including direct mixing and roller compaction process.) Exemplary compositions for those processes are reproduced below.
    TABLE 2
    Preferred Naloxone Ranges for Differing Strengths of Oxycodone Tablets
    Oxycodone (mg) 10 20 40 80 160
    Naloxone (mg) 2-10 4-20 8-40 16-80 20-160
  • [0034]
    For oxymorphone, the doses for controlled release tablets may be 10, 20, or 40 mg and the naloxone dose ranges may be the same as set forth for oxycodone.
  • [0035]
    The preferred oxycodone:naloxone ratio is 5:1 to 1:1.
    TABLE 3
    Formula 1 of Oxycodone HCl 10-mg Tablets with Naloxone
    Component mg/Tablet percent (by wt)
    Oxycodone Hydrochloride 10.00 2.22%
    Naloxone 10.00 2.22%
    Lactose (spray-dried) 281.50 62.56%
    Hydroxypropyl Methylcellulose, 135.00 30.00%
    K100M
    Silicone Dioxide 9.00 2.00%
    Magnesium Stearate 4.50 1.00%
    Total: 450.00 100.00%
  • [0036]
    [0036]
    TABLE 4
    Formula 2 of Oxycodone HCl 10-mg Tablets with Naloxone
    Component mg/Tablet percent (by wt)
    Oxycodone Hydrochloride 10.00 3.77%
    Naloxone 10.00 3.77%
    Lactose (spray-dried) 157.55 59.45%
    Hydroxypropyl Methylcellulose, 79.50 30.00%
    K100M
    Silicone Dioxide 5.30 2.00%
    Magnesium Stearate 2.65 1.00%
    Total: 265.00 100.00%
  • [0037]
    [0037]
    TABLE 5
    Formula 3 of Oxycodone HCl 10-mg Tablets with Naloxone
    Component mg/Tablet percent (by wt)
    Oxycodone Hydrochloride 10.00 8.33%
    Naloxone 10.00 8.33%
    Lactose (spray-dried) 60.40 50.33%
    Hydroxypropyl Methylcellulose, 36.00 30.00%
    K100M
    Silicone Dioxide 2.40 2.00%
    Magnesium Stearate 1.20 1.00%
    Total: 120.00 100.00%
  • [0038]
    Alternate compositions may also be used. Preferably, tablets according to the present invention will have the following compositions:
    Material Quantity (%)
    Oxycodone Hydrochloride, USP  2.000-35.000
    Naloxone  2.000-20.000
    Microcrystalline Cellulose, NF (Avicel PH102) 10.000-50.000
    Ammonio Methacrylate Copolymer, NF (Eudragit RSPO) 30.000-70.000
    Colloidal Silicon Dioxide, NF (Cab-O-Sil)    0-5.000
    Sodium Lauryl Sulfate, NF    0-5.000
    Magnesium Hydroxide, USP    0-2.000
    Povidone, USP    0-15.000
    Stearic Acid, NF    0-5.000
    Magnesium Stearate, NF    0-5.000
  • [0039]
    Dissolution was conducted according to USP XXIV Apparatus 3 (Reciprocating Cylinder) for Formulation 1-3. The apparatus 3 is to simulate the gastrointestinal conditions of human. The 1 st hour is at pH 1.2 of 0.1N HCl. The 2nd and 3rd hours are at pH 4.5 of 10 mM of potassium phosphate monobasic. The conditions after the 3rd hours are at pH 6.8 of 10 mM of potassium phosphate monobasic. All dissolution vessels contain 250 mL of dissolution solution. The dip rate is set at 10 dips per minute. The bath temperature is set at 37.5° C. The HPLC parameters are set as follows: Column—Inertsil ODS 3, 50 mm×4.6 mm, 3 μm particle size. Mobile phase: 80% 30 mM sodium hexanesulfonate pH 3.0+/−1, 20% acetonitrile. Injection volume is 75 μL. Column temperature is 35° C., Flow rate is set at 1.0 mL/min. Wavelength is set at 225 nm. Run time is 5.5 minutes.
  • [0040]
    Dissolution results for Formulation 1-3 were as follows:
    Formulation 1
    Tablet not Crushed Tablet Crushed
    % Oxycodone % Naloxone % Oxycodone % Naloxone
    Time Dissolved Dissolved Dissolved Dissolved
    0 0.0 0.0 0.0 0.0
    1 29.8 27.8 88.2 94.6
    2 47.8 45.4
    3 59.8 57.4
    4 68.5 65.9
    8 91.1 87.5
    12 100.7 97.9
  • [0041]
    [0041]
    Formulation 2
    Tablet not Crushed Tablet Crushed
    % Oxycodone % Naloxone % Oxycodone % Naloxone
    Time Dissolved Dissolved Dissolved Dissolved
    0 0.0 0.0 0.0 0.0
    1 40.1 37.0 104.9 102.8
    2 63.2 60.3
    3 77.3 75.3
    4 86.5 85.2
    8 105.6 106.1
    12 110.5 112.6
  • [0042]
    [0042]
    Formulation 3
    Tablet not Crushed Tablet Crushed
    % Oxycodone % Naloxone % Oxycodone % Naloxone
    Time Dissolved Dissolved Dissolved Dissolved
    0 0.0 0.0 0.0 0.0
    1 59.0 52.5 100.5 90.9
    2 85.4 78.0
    3 97.4 90.3
    4 102.5 95.9
    8 105.4 99.7
    12 105.4 99.8
  • [0043]
    From these tests, it is evident that under normal, non-crushing use, the amount of antagonist, here naloxone, released over time is insufficient to block the opioid effect. Even Example 3 which has the highest initial release rate of antagonist, only makes about 5 mg naloxone available in the first hour. Due to the short half-life of naloxone, and the slow release rate, the antagonist does not accumulate in the body to a level that blocks the opioid effect. On the other hand, in the crushed tablet, substantially all of the antagonist is available in the first hour. Thus, an opioid blocking amount of antagonist is readily available to deter oral and other forms of abuse. Regardless of the antagonist used, the combination of the antagonist content, the release rate, and the antagonist half-life achieves the goals of the invention to block the opioid effect when administered as for instant release, yet not blocking the opioid effect when administered as intended and recommended as a controlled release formulation.
  • [0044]
    It is well known that the various opioids have differing relative strengths. Often, these are compared and related to a standard for determining relative doses of each. Although this application discusses opioid content in terms of oxycodone, those skilled in the art will readily appreciate that other opioids, stronger and weaker, can be used in equivalent dosage amounts. Likewise, the antagonist is similarly selected and dosed.
  • [0045]
    The scope of the invention is not limited to the above examples, which are provided only for purposes of illustration. The above description is written in the context of a tablet. Other oral dosage forms, capable of being made in CR formulations may be used. Among the oral dosage forms available are capsules, caplets, microspheres, gel caps and even liquid formulations.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3966940 *Sep 2, 1975Jun 29, 1976Bristol-Myers CompanyAnalgetic compositions
US4457933 *Dec 11, 1981Jul 3, 1984Bristol-Myers CompanyPrevention of analgesic abuse
US5472943 *Jul 27, 1993Dec 5, 1995Albert Einstein College Of Medicine Of Yeshiva University,Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5512578 *Jul 19, 1994Apr 30, 1996Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva UniversityMethod of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5580876 *Nov 3, 1995Dec 3, 1996Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva UniversityMethod of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5767125 *Dec 3, 1996Jun 16, 1998Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva UniversityMethod of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6228863 *Dec 22, 1998May 8, 2001Euro-Celtique S.A.Method of preventing abuse of opioid dosage forms
US6277384 *Dec 22, 1998Aug 21, 2001Euro-Celtique S.A.Opioid agonist/antagonist combinations
US6387404 *Feb 6, 2001May 14, 2002Euro-Celtique S.A.Immediate release tablet cores of insoluble drugs having sustained-release coating
US6451806 *Nov 29, 2000Sep 17, 2002Adolor CorporationMethods and compositions involving opioids and antagonists thereof
US6627635 *Mar 22, 2001Sep 30, 2003Euro-Celtique S.A.Method of preventing abuse of opioid dosage forms
US6696088 *Feb 8, 2001Feb 24, 2004Euro-Celtique, S.A.Tamper-resistant oral opioid agonist formulations
US20030004177 *May 10, 2002Jan 2, 2003Endo Pharmaceuticals, Inc.Abuse-resistant opioid dosage form
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7276250Jul 3, 2002Oct 2, 2007Penwest Pharmaceuticals CompanySustained release formulations of oxymorphone
US7682633Mar 6, 2009Mar 23, 2010Alpharma Pharmaceuticals, LlcPharmaceutical composition
US7682634Mar 23, 2010Alpharma Pharmaceuticals, LlcPharmaceutical compositions
US7815934Sep 22, 2003Oct 19, 2010Alpharma Pharmaceuticals, LlcSequestering subunit and related compositions and methods
US7827983Nov 9, 2010Hewlett-Packard Development Company, L.P.Method for making a pharmaceutically active ingredient abuse-prevention device
US8158156Jun 19, 2007Apr 17, 2012Alpharma Pharmaceuticals, LlcAbuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US8182836Jun 5, 2009May 22, 2012Elite Laboratories, Inc.Abuse-resistant oral dosage forms and method of use thereof
US8298579Mar 23, 2005Oct 30, 2012Euro-Celtique S.A.Tamper resistant dosage form comprising an adsorbent and an adverse agent
US8309122Feb 28, 2007Nov 13, 2012Endo Pharmaceuticals Inc.Oxymorphone controlled release formulations
US8329216Dec 11, 2012Endo Pharmaceuticals Inc.Oxymorphone controlled release formulations
US8362029Dec 31, 2009Jan 29, 2013Upsher-Smith Laboratories, Inc.Opioid-containing oral pharmaceutical compositions and methods
US8425933Apr 23, 2013Elite Laboratories, Inc.Abuse-resistant oral dosage forms and method of use thereof
US8460640Dec 14, 2009Jun 11, 2013Paladin Labs, Inc.Narcotic drug formulations with decreased abuse potential
US8486448Dec 16, 2008Jul 16, 2013Paladin Labs Inc.Misuse preventative, controlled release formulation
US8486449Dec 16, 2009Jul 16, 2013Paladin Labs Inc.Misuse preventative, controlled release formulation
US8623412Sep 23, 2003Jan 7, 2014Elan Pharma International LimitedAbuse-resistant pharmaceutical compositions
US8623418Dec 16, 2008Jan 7, 2014Alpharma Pharmaceuticals LlcPharmaceutical composition
US8673355Dec 27, 2011Mar 18, 2014Purdue Pharma L.P.Opioid agonist/antagonist combinations
US8685443Apr 23, 2010Apr 1, 2014Alpharma Pharmaceuticals LlcSequestering subunit and related compositions and methods
US8685444Apr 23, 2010Apr 1, 2014Alpharma Pharmaceuticals LlcSequestering subunit and related compositions and methods
US8685447Jun 17, 2013Apr 1, 2014Paladin Labs Inc.Misuse preventative, controlled release formulation
US8691270Jun 17, 2013Apr 8, 2014Paladin Labs Inc.Misuse preventative, controlled release formulation
US8703186Apr 16, 2013Apr 22, 2014Elite Laboratories, Inc.Abuse-resistant oral dosage forms and method of use thereof
US8778382Apr 30, 2004Jul 15, 2014Purdue Pharma L.P.Tamper resistant transdermal dosage form
US8790689Nov 18, 2005Jul 29, 2014Purdue Pharma L.P.Tamper resistant transdermal dosage form
US8815289May 23, 2013Aug 26, 2014Purdue Pharma L.P.Tamper resistant dosage forms
US8821929May 23, 2013Sep 2, 2014Purdue Pharma L.P.Tamper resistant dosage forms
US8822487Dec 7, 2012Sep 2, 2014Purdue Pharma L.P.Opioid agonist/opioid antagonist/acetaminophen combinations
US8834925May 23, 2013Sep 16, 2014Purdue Pharma L.P.Tamper resistant dosage forms
US8846086May 23, 2013Sep 30, 2014Purdue Pharma L.P.Tamper resistant dosage forms
US8846090 *Jan 11, 2012Sep 30, 2014Euro-Celtique S.A.Matrix for sustained, invariant and independent release of active compounds
US8846091Oct 18, 2013Sep 30, 2014Euro-Celtique S.A.Matrix for sustained, invariant and independent release of active compounds
US8846104Feb 13, 2012Sep 30, 2014Alpharma Pharmaceuticals LlcPharmaceutical compositions for the deterrence and/or prevention of abuse
US8877247Feb 22, 2010Nov 4, 2014Alpharma Pharmaceuticals LlcAbuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US8894987Aug 24, 2007Nov 25, 2014William H. McKennaTamper resistant dosage forms
US8894988May 23, 2013Nov 25, 2014Purdue Pharma L.P.Tamper resistant dosage forms
US8911719May 23, 2013Dec 16, 2014Purdue Pharma LpTamper resistant dosage forms
US8920833Mar 3, 2014Dec 30, 2014Paladin Labs Inc.Misuse preventative, controlled release formulation
US8920834Jun 16, 2014Dec 30, 2014Paladin Labs Inc.Misuse preventative, controlled release formulation
US8927013Mar 3, 2014Jan 6, 2015Paladin Labs Inc.Misuse preventative, controlled release formulation
US8927014Jun 16, 2014Jan 6, 2015Paladin Labs Inc.Misuse preventative, controlled release formulation
US8932630Sep 18, 2014Jan 13, 2015Purdue Pharma L.POpioid agonist/antagonist combinations
US8936808Sep 18, 2014Jan 20, 2015Purdue Pharma L.P.Opioid agonist/opioid antagonist/acetaminophen combinations
US8969369Dec 20, 2013Mar 3, 2015Purdue Pharma L.P.Abuse-resistant controlled-release opioid dosage form
US8987291Dec 14, 2012Mar 24, 2015Upsher Smith Laboratories, Inc.Opioid-containing oral pharmaceutical compositions and methods
US9023390Dec 31, 2009May 5, 2015Upsher-Smith Laboratories, Inc.Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
US9056051Mar 11, 2014Jun 16, 2015Purdue Pharma L.P.Abuse-resistant controlled-release opioid dosage form
US9084729Oct 30, 2013Jul 21, 2015Purdue Pharma L.P.Abuse-resistant controlled-release opioid dosage form
US9084816Oct 16, 2014Jul 21, 2015Purdue Pharma L.P.Tamper resistant dosage forms
US9095614Oct 16, 2014Aug 4, 2015Purdue Pharma L.P.Tamper resistant dosage forms
US9095615Oct 16, 2014Aug 4, 2015Purdue Pharma L.P.Tamper resistant dosage forms
US9101625Aug 29, 2007Aug 11, 2015Purdue Pharma L.P.Buprenorphine-wafer for drug substitution therapy
US9101661Oct 16, 2014Aug 11, 2015Purdue Pharma L.P.Tamper resistant dosage forms
US9161937May 29, 2015Oct 20, 2015Purdue Pharma L.P.Abuse-resistant controlled-release opioid dosage form
US9168252May 29, 2015Oct 27, 2015Purdue Pharma L.P.Abuse-resistant controlled-release opioid dosage form
US9205082Mar 14, 2014Dec 8, 2015Purdue Pharma L.P.Opioid agonist/antagonist combinations
US9271940Mar 10, 2010Mar 1, 2016Purdue Pharma L.P.Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US9283216Sep 18, 2015Mar 15, 2016Purdue Pharma L.P.Abuse-resistant controlled-release opioid dosage form
US9283221Sep 18, 2015Mar 15, 2016Purdue Pharma L.P.Abuse-resistant controlled-release opioid dosage form
US9345701Feb 3, 2016May 24, 2016Purdue Pharma L.P.Abuse-resistant controlled-release opioid dosage form
US9358230Feb 3, 2016Jun 7, 2016Purdue Pharma L.P.Abuse-resistant controlled-release opioid dosage form
US9370512Jul 15, 2015Jun 21, 2016Purdue Pharma L.P.Buprenorphine-wafer for drug substitution therapy
US20030091635 *Sep 25, 2002May 15, 2003Baichwal Anand R.Opioid formulations having reduced potential for abuse
US20030129230 *Jul 3, 2002Jul 10, 2003Penwest Pharmaceuticals CompanySustained release formulations of oxymorphone
US20030129234 *Jul 3, 2002Jul 10, 2003Penwest Pharmaceuticals CompanyMethods of making sustained release formulations of oxymorphone
US20040131552 *Sep 22, 2003Jul 8, 2004Alpharma, Inc.Sequestering subunit and related compositions and methods
US20040202717 *Apr 8, 2003Oct 14, 2004Mehta Atul M.Abuse-resistant oral dosage forms and method of use thereof
US20050002997 *Apr 30, 2004Jan 6, 2005Howard Stephen A.Tamper resistant transdermal dosage form
US20060104909 *Sep 23, 2003May 18, 2006Farid VaghefiAbuse-resistant pharmaceutical compositions
US20060130828 *Dec 20, 2004Jun 22, 2006Sexton Douglas AMethod for making a pharmaceutically active ingredient abuse-prevention device
US20060198881 *Nov 18, 2005Sep 7, 2006Purdue Pharma L.P.Tamper resistant transdermal dosage form
US20070098794 *Jun 29, 2006May 3, 2007Haui-Hung KaoOxymorphone controlled release formulations
US20070134328 *Feb 28, 2007Jun 14, 2007Endo Pharmaceuticals, Inc.Oxymorphone controlled release formulations
US20070140975 *Feb 9, 2007Jun 21, 2007Penwest Pharmaceuticals Co.Opioid formulations having reduced potential for abuse
US20070185145 *Feb 3, 2006Aug 9, 2007Royds Robert BPharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
US20070185147 *Jun 1, 2005Aug 9, 2007Euro-Celtique S.A.Opioids for the treatment of the restless leg syndrome
US20070207089 *Mar 23, 2005Sep 6, 2007Osvaldo AbreuTamper Resistant Dosage Form Comprising an Adsorbent and an Adverse Agent
US20070212414 *Mar 8, 2006Sep 13, 2007Penwest Pharmaceuticals Co.Ethanol-resistant sustained release formulations
US20080233197 *Jun 19, 2007Sep 25, 2008Francis Joseph MatthewsPharmaceutical compositions
US20090081290 *Aug 24, 2007Mar 26, 2009Purdue Pharma L.P.Tamper resistant dosage forms
US20090124650 *Jun 21, 2007May 14, 2009Endo Pharmaceuticals, Inc.Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US20090162450 *Mar 6, 2009Jun 25, 2009Alpharma Pharmaceuticals, Llc.Pharmaceutical composition
US20090175937 *Dec 16, 2008Jul 9, 2009Labopharm, Inc.Misuse Preventative, Controlled Release Formulation
US20090238868 *Jun 5, 2009Sep 24, 2009Elite Laboratories, Inc.Abuse-resistant oral dosage forms and method of use thereof
US20100098771 *Dec 17, 2009Apr 22, 2010Elite Laboratories, Inc.Abuse-resistant oral dosage forms and method of use thereof
US20100143483 *Feb 22, 2010Jun 10, 2010Alpharma Pharmaceuticals, Llc.Pharmaceutical compositions
US20100151014 *Dec 16, 2008Jun 17, 2010Alpharma Pharmaceuticals, LlcPharmaceutical composition
US20100152221 *Dec 16, 2008Jun 17, 2010Alpharma Pharmaceuticals, LlcPharmaceutical composition
US20100239662 *Sep 23, 2010Miloud RahmouniMisuse preventative, controlled release formulation
US20100266645 *Dec 16, 2008Oct 21, 2010Alfred LiangPharmaceutical compositions
US20110014280 *Jan 20, 2011Garth BoehmSequestering subunit and related compositions and methods
US20110027455 *Apr 23, 2010Feb 3, 2011Garth BoehmSequestering subunit and related compositions and methods
US20110097401 *Apr 28, 2011Meritage Pharma, Inc.Methods for treating gastrointestinal disorders
US20110135731 *Jun 9, 2011Endo Pharmaceuticals, Inc.Abuse-resistant opioid dosage form
US20110177133 *Jul 7, 2009Jul 21, 2011Michael HoppUse of opioid antagonists for treating urinary retention
US20110237615 *Dec 14, 2009Sep 29, 2011Paladin Labs Inc.Narcotic Drug Formulations with Decreased Abuse Potential
US20120172387 *Jul 5, 2012Euro-Celtique S.A.Opioids for the treatment of the restless leg syndrome
US20120183612 *Jul 19, 2012Euro-Celtique S.A.Matrix for sustained, invariant and independent release of active compounds
US20120225901 *Dec 16, 2011Sep 6, 2012Euro-Celtique S.A.Dosage form containing oxycodone and naloxone
US20140031382 *Oct 2, 2013Jan 30, 2014Euro-Celtique S.A.Dosage form containing oxycodone and naloxone
WO2015066172A1 *Oct 29, 2014May 7, 2015Cima Labs Inc.Immediate release abuse-deterrent granulated dosage forms
Classifications
U.S. Classification514/282, 424/468
International ClassificationA61K9/22, A61K31/135, A61K31/473, A61K47/38, A61K47/32, A61K45/00, A61K47/04, A61K47/12, A61K47/20, A61P25/04, A61K9/20, A61K31/485
Cooperative ClassificationA61K31/485, A61K31/46, A61K9/20, A61K9/2054, A61K9/2027, A61K9/2018, A61K9/0002
European ClassificationA61K31/485, A61K9/20H6F2, A61K9/20H6B, A61K9/20H4B
Legal Events
DateCodeEventDescription
May 10, 2002ASAssignment
Owner name: ENDO PHARMACEUTICALS, INC., PENNSYLVANIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CARUSO, FRANK S.;KAO, HUAI-HUNG;REEL/FRAME:012895/0330
Effective date: 20020509
Feb 12, 2014ASAssignment
Owner name: PURDUE PHARMA, CANADA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ENDO PHARMACEUTICALS INC.;REEL/FRAME:032207/0554
Effective date: 20131029
May 6, 2014ASAssignment
Owner name: PURDUE PHARMA L.P., CONNECTICUT
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PURDUE PHARMA;REEL/FRAME:032829/0655
Effective date: 20140505